Patents by Inventor Luigi Warren
Luigi Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220162565Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: October 28, 2021Publication date: May 26, 2022Applicant: 55 Shattuck StreetInventors: Derrick ROSSI, Luigi WARREN
-
Publication number: 20220008482Abstract: Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.Type: ApplicationFiled: June 13, 2019Publication date: January 13, 2022Inventor: Luigi WARREN
-
Patent number: 11186829Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: May 28, 2019Date of Patent: November 30, 2021Assignee: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Publication number: 20210196763Abstract: Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.Type: ApplicationFiled: June 13, 2019Publication date: July 1, 2021Inventor: Luigi WARREN
-
Patent number: 10815463Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.Type: GrantFiled: November 7, 2017Date of Patent: October 27, 2020Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
-
Publication number: 20190382729Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: May 28, 2019Publication date: December 19, 2019Applicant: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Patent number: 10344265Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: August 31, 2017Date of Patent: July 9, 2019Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Derrick Rossi, Luigi Warren
-
Patent number: 10155929Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.Type: GrantFiled: May 13, 2013Date of Patent: December 18, 2018Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.Inventors: Jiwu Wang, Luigi Warren, Yuhui Ni
-
Publication number: 20180216078Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: August 31, 2017Publication date: August 2, 2018Applicant: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Publication number: 20180051262Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.Type: ApplicationFiled: November 7, 2017Publication date: February 22, 2018Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
-
Patent number: 9803177Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: June 23, 2014Date of Patent: October 31, 2017Assignee: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Publication number: 20160130567Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.Type: ApplicationFiled: November 1, 2015Publication date: May 12, 2016Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
-
Patent number: 8883506Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: August 21, 2012Date of Patent: November 11, 2014Assignee: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Publication number: 20140308746Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: June 23, 2014Publication date: October 16, 2014Inventors: Derrick Rossi, Luigi Warren
-
Patent number: 8802438Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: April 15, 2011Date of Patent: August 12, 2014Assignee: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Patent number: 8716465Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: GrantFiled: August 21, 2012Date of Patent: May 6, 2014Assignee: Children's Medical Center CorporationInventors: Derrick Rossi, Luigi Warren
-
Publication number: 20130302295Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.Type: ApplicationFiled: May 13, 2013Publication date: November 14, 2013Inventors: Jiwu WANG, Luigi WARREN, Yuhui NI
-
Publication number: 20120322865Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren
-
Publication number: 20120322864Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren
-
Publication number: 20120046346Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: April 15, 2011Publication date: February 23, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren